A Phase 2, Open Label, Study of VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL), (AIN2, AIN3, PAIN2, PAIN3) in Individuals That Are Seronegative for Human Immunodeficiency Virus (HIV)-1/2
Latest Information Update: 05 Jul 2023
At a glance
- Drugs Bizalimogene ralaplasmid (Primary)
- Indications Anal dysplasia; Anal intraepithelial neoplasia
- Focus Proof of concept; Therapeutic Use
- Sponsors Inovio Pharmaceuticals
- 15 Nov 2021 According to an Inovio Pharmaceuticals media release, results from this trial will be presented at the 34th International Papillomavirus Conference (IPVC) 2021.
- 15 Jun 2021 Status changed from active, no longer recruiting to completed.
- 09 Dec 2020 Results published in the Inovio Pharmaceuticals media release